13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001600004
Total reported value
$1.6B
$1.6B
38 檔
20.5%
As reported in its official Q3 2024 Form 13F filing, First Light Asset Management, LLC's tracked investment portfolio stood at $1.6B with 38 total positions.
In Q3 2024, First Light Asset Management, LLC adopted a defensive or profit-taking posture, trimming 19 positions and completely liquidating 11 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 7.90% | -5.56% | EXIT | |
| 2 | FNAUSD | Paragon 28 Inc | Stock-Other | 5.64% | — | +24.22% | |
| 3 | EVH | Evolent Health Inc - A | Stock-Other | 5.41% | — | +59.02% | |
| 4 | AXGN | Axogen Inc | Stock-Other | 4.77% | -4.16% | +22.32% | |
| 5 | ATRC | Atricure Inc | Stock-Other | 4.35% | -0.90% | -5.05% | |
| 6 | INSM | Insmed Inc | Stock-Healthcare | 4.18% | — | +24.96% | |
| 7 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 4.01% | -0.45% | -21.40% | |
| 8 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.87% | — | -9.54% | |
| 9 | NEO | Neogenomics Inc | Stock-Healthcare | 3.78% | +4.42% | -18.66% | |
| 10 | DYN | Dyne Therapeutics Inc | Stock-Other | 3.76% | — | +228.76% | |
| 11 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 3.62% | +0.84% | +44.72% | |
| 12 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 3.49% | — | -21.60% | |
| 13 | PFMTUSD | Performant Financial CORP | Stock-Other | 3.49% | — | +6.62% | |
| 14 | TMDX | Transmedics Group Inc | Stock-Healthcare | 3.47% | — | -11.60% | |
| 15 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 3.12% | — | -5.36% | |
| 16 | PODD | Insulet CORP | Stock-Healthcare | 3.08% | — | -26.23% | |
| 17 | HCAT | Health Catalyst Inc | Stock-Other | 2.91% | +0.08% | +8.60% | |
| 18 | ANAB | Anaptysbio Inc | Stock-Other | 2.64% | -0.42% | +21.69% | |
| 19 | PPHMEUR | Avid Bioservices Inc | Stock-Other | 2.62% | — | — | |
| 20 | VERA | Vera Therapeutics Inc | Stock-Other | 2.59% | -1.13% | EXIT | |
| 21 | PLRX | Pliant Therapeutics Inc | Stock-Other | 2.40% | — | -24.28% | |
| 22 | RGEN | Repligen CORP | Stock-Healthcare | 2.05% | — | — | |
| 23 | NTRA | Natera Inc | Stock-Healthcare | 1.95% | — | -49.89% | |
| 24 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.85% | — | -14.29% | |
| 25 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 1.82% | — | -30.17% | |
| 26 | SIBN | Si-bone Inc | Stock-Other | 1.78% | +2.00% | -38.29% | |
| 27 | KYMR | Kymera Therapeutics Inc | Stock-Other | 1.60% | — | — | |
| 28 | KRMD | Koru Medical Systems Inc | Stock-Other | 1.27% | -0.60% | +11.13% | |
| 29 | GH | Guardant Health Inc | Stock-Healthcare | 1.24% | +1.71% | +55.65% | |
| 30 | OPRX | Optimizerx CORP | Stock-Other | 1.16% | — | -0.84% | |
| 31 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.91% | — | — | |
| 32 | AVTR | Avantor Inc | Stock-Healthcare | 0.77% | — | -39.75% | |
| 33 | MOH | Molina Healthcare Inc | Stock-Healthcare | 0.76% | — | — | |
| 34 | ASND | Ascendis Pharma A/S | Stock-Other | 0.64% | — | +43.05% | |
| 35 | NARIUSD | Inari Medical Inc | Stock-Other | 0.60% | — | -63.04% | |
| 36 | EXK | Exact Sciences CORP | Stock-Materials | 0.39% | — | -44.61% | |
| 37 | ATEC | Alphatec Holdings Inc | Stock-Other | 0.06% | — | -97.41% | |
| 38 | ✓ | Stock-Other | 0.02% | — | +14.44% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | 260 | Centessa Pharmaceuticals-adr | +4.1% | +24.26% | Add |
| 2 | EVH | Evolent Health Inc - A | +3% | +59.02% | Add |
| 3 | AXGN | Axogen Inc | +2.7% | +22.32% | Add |
| 4 | PPHMEUR | Avid Bioservices Inc | +2.6% | NEW | New buy |
| 5 | DYN | Dyne Therapeutics Inc | +2.6% | +228.76% | Add |
| 6 | RGEN | Repligen CORP | +2.1% | NEW | New buy |
| 7 | KYMR | Kymera Therapeutics Inc | +1.6% | NEW | New buy |
| 8 | TNDM | Tandem Diabetes Care Inc | +1.1% | +44.72% | Add |
| 9 | INSM | Insmed Inc | +0.9% | +24.96% | Add |
| 10 | ANAB | Anaptysbio Inc | +0.9% | +21.69% | Add |
| 11 | RLAY | Relay Therapeutics Inc | +0.9% | NEW | New buy |
| 12 | PFMTUSD | Performant Financial CORP | +0.8% | +6.62% | Add |
| 13 | MOH | Molina Healthcare Inc | +0.8% | NEW | New buy |
| 14 | FNAUSD | Paragon 28 Inc | +0.7% | +24.22% | Add |
| 15 | HCAT | Health Catalyst Inc | +0.7% | +8.60% | Add |
| 16 | OSCR | Oscar Health Inc - Class A | +0.5% | -5.36% | Trim |
| 17 | ATRC | Atricure Inc | +0.4% | -5.05% | Trim |
| 18 | ASND | Ascendis Pharma A/S | +0.2% | +43.05% | Add |
| 19 | GH | Guardant Health Inc | +0.2% | +55.65% | Add |
| 20 | KRMD | Koru Medical Systems Inc | +0.1% | +11.13% | Add |
| 21 | RARE | Ultragenyx Pharmaceutical In | 0% | -21.60% | Trim |
| 22 | ✓ | 0% | +14.44% | Add | |
| 23 | EXK | Exact Sciences CORP | -0.1% | -44.61% | Trim |
| 24 | SLP | Simulations Plus Inc | -0.1% | EXIT | Sold out |
| 25 | GPCR | Structure Therapeutics Inc | -0.2% | -14.29% | Trim |
| 26 | INSP | Inspire Medical Systems Inc | -0.3% | EXIT | Sold out |
| 27 | AVTR | Avantor Inc | -0.3% | -39.75% | Trim |
| 28 | STVN | Stevanato Group S.p.A. | -0.4% | EXIT | Sold out |
| 29 | OPRX | Optimizerx CORP | -0.4% | -0.84% | Trim |
| 30 | TMDX | Transmedics Group Inc | -0.5% | -11.60% | Trim |
| 31 | CNC | Centene CORP | -0.5% | EXIT | Sold out |
| 32 | HUM | Humana Inc | -0.5% | EXIT | Sold out |
| 33 | XENE | Xenon Pharmaceuticals Inc | -0.6% | -9.54% | Trim |
| 34 | VERA | Vera Therapeutics Inc | -0.6% | -29.88% | Trim |
| 35 | BCYC | Bicycle Therapeutics Plc-adr | -0.6% | -30.17% | Trim |
| 36 | PEN | Penumbra Inc | -0.7% | EXIT | Sold out |
| 37 | CRNX | Crinetics Pharmaceuticals In | -0.7% | -21.40% | Trim |
| 38 | SVRA | Savara Inc | -0.7% | EXIT | Sold out |
| 39 | PODD | Insulet CORP | -0.7% | -26.23% | Trim |
| 40 | PLRX | Pliant Therapeutics Inc | -0.8% | -24.28% | Trim |
| 41 | NEO | Neogenomics Inc | -0.8% | -18.66% | Trim |
| 42 | PCVX | Vaxcyte Inc | -0.9% | EXIT | Sold out |
| 43 | SIBN | Si-bone Inc | -1% | -38.29% | Trim |
| 44 | NARIUSD | Inari Medical Inc | -1.4% | -63.04% | Trim |
| 45 | TCMD | Tactile Systems Technology I | -1.4% | EXIT | Sold out |
| 46 | NTRA | Natera Inc | -1.6% | -49.89% | Trim |
| 47 | RCM1USD | R1 Rcm Inc | -2.7% | EXIT | Sold out |
| 48 | LIVN | LivaNova PLC | -3.4% | EXIT | Sold out |
| 49 | ATEC | Alphatec Holdings Inc | -4.8% | -97.41% | Trim |
According to official SEC Form 13F filings, First Light Asset Management, LLC reported a total U.S. public equity portfolio value of $1.6B across 38 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including 260, FNAUSD, EVH) accounted for 20.5% of total reported equity market value during Q3 2024.
Top New Position Initiated
PPHMEUR
市值: $31.5M
Top Position Liquidated / Trimmed
LIVN
前期市值: $38.9M
During Q3 2024, First Light Asset Management, LLC's top holdings by market value included 260 (7.9%)、FNAUSD (5.6%)、EVH (5.4%). The largest single position, 260, represented 7.9% of total portfolio value.
In Q3 2024, First Light Asset Management, LLC made 49 total portfolio adjustments, initiating 5 new buys, adding to 14 positions, trimming 19 holdings, and fully liquidating 11 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.